Robert is an executive partner at Flagship Pioneering and chairman of CiBO Technologies and Invaio Sciences as well as a board member at Inari.

Dean’s unique background as an entrepreneur, technologist, innovator, and business executive provides a strong foundation as he stewards Indigo Ag into this next critical phase of growth and profitability, to ultimately realize the full potential of the Indigo Ag platform for companies, farmers, and the planet. 

Geoffrey has co-founded companies that have, in aggregate, achieved over $10 billion in public and private market capitalization. Through his role in Flagship Labs, the company’s innovation foundry, Geoffrey has created companies that include Quotient Therapeutics, Tessera Therapeutics, Generate:Biomedicines, Indigo Agriculture, Sana Biotechnology (NASDAQ: SANA), and Seres Therapeutics (NASDAQ: MCRB). These are pioneering, respectively, somatic genomics, Gene Writing™, generative biology, carbon farming and plant microbiome products, engineered cells and cell-specific gene therapies, and the first human microbiome therapeutics.

Geoffrey currently serves as CEO of Quotient Therapeutics, board chair of Tessera Therapeutics, chief innovation officer and board director of Indigo Agriculture, board director of Generate:Biomedicines, and as CEO of multiple new stealth therapeutics and sustainability companies. Geoffrey has served as founding chief executive officer of several Flagship companies including: Tessera Therapeutics, where he led the development of its pioneering Gene Writing™ technology; Cobalt Biomedicine, which he led from inception to merger with Sana Biotechnology; and Indigo, where he led the development of the company’s plant microbiome platform and the discovery of the company’s first commercial products: Indigo Cotton, Indigo Wheat, Indigo Corn, and Indigo Soy, which are now used on millions of acres. Previously, Geoffrey was the chief technology officer of Seres Therapeutics, where he led the discovery of SER-109, the first microbiome therapeutic to report positive Phase 3 data, and built out the company’s discovery platform.

Geoffrey has deep expertise in genome engineering, the microbiome, bioengineering, and nanotechnology. He is listed as an inventor on over 200 patent applications and patents, and he has co-authored more than 20 peer-reviewed articles. Geoffrey has received a number of awards and honors, including Bloomberg 50's Ones to Watch; Business Insider’s 30 Biotech Leaders Under 40; Endpoints 20 Biopharma Leaders Under 40; Fierce Pharma’s Most Influential People in Biopharma; Codex’s World’s Top 50 Innovators; Boston Chamber of Commerce Ten Outstanding Young Leaders; the prestigious Lemelson-MIT Student Prize, awarded to the most innovative students at MIT; the National Inventors Hall of Fame Graduate Student Prize; the Biomedical Engineering Society Graduate Research Award; and the Harvard-MIT Martha Gray Prize. Geoffrey and his inventions have been profiled by Forbes, The Economist, CNN, Bloomberg, WIRED, Fast Company, Business Insider, Scientific American, Popular Science, Boston Globe, TechCrunch, Barron’s, Endpoints, Fierce Biotech, MIT Technology Review, and other media.

Geoffrey was awarded a PhD in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N. Bhatia, MD, PhD; an MS in bioengineering from the University of California, San Diego; and an SB in chemical engineering from MIT.

Before joining Indigo’s Board, Andreas served as Chairman and CEO of International Flavors & Fragrances, Inc. (“IFF”), an industry leader in food ingredients, beverage, scent, health, and biosciences. For those seven years, he was responsible for worldwide operations, representing nearly $11B in annual revenues and over 24,000 employees. At IFF, Andreas led the company through a transformational period, which included overseeing the integration of DuPont Nutrition & Biosciences into the company, leading the organization’s heralded sustainability efforts (conception and implementation of the “Do More Good” plan), and driving strong sales growth.

Prior to IFF, Andreas served for many years in various senior leadership roles at Bayer AG and Pfizer, giving him extensive experience in international business, product development and strategic planning. Andreas also served on the Boards of Directors for Bunge Limited (NYSE: BG), a leading global agribusiness and food company, and Novo Nordisk (NYSE: NVO), a leading global healthcare company. Andreas brings to Indigo valuable knowledge of the global agricultural trading business and how it operates within the broader ag and food supply chain.

As a member of the board, Andreas provides insight and support as Indigo expands access to its sustainability solutions for Consumer-Packaged Goods and corporate customers around the world.

John most recently served as Interim Chief Financial Officer at Lamb Weston Holdings, Inc., a spinoff from Conagra Brands. Prior to this, he held several leadership positions at ConAgra Foods, acting as the company’s Executive Vice President and CFO up until August 2016. After joining the company in 2002, John stepped into a variety of roles, beginning as ConAgra’s Vice President of Internal Audit and becoming, in turn, Acting CFO, Senior Vice President, and Corporate Controller. Leading up to his long tenure at ConAgra, John was a Partner at Ernst and Young, spearheading the company’s business risk services in the Ohio Valley area.

Early in his professional career, John was an Auditor with PepsiCo and KPMG Peat Marwick. He earned his B.A. in Business Administration from Miami University’s Richard T Farmer School of Business Administration.

Founded in 2000, Flagship is an enterprise where entrepreneurially-minded scientists invent seemingly unreasonable solutions to challenges facing human health and sustainability. They begin by asking “What if?” and iterate toward the unexpected answers resulting in the creation of first-in-category bioplatform companies with significant impact. Flagship has developed more than 100 scientific ventures resulting in over $100 billion in aggregate value, thousands of patents and patent applications, and more than 50 drugs in clinical development.

During his career as inventor, entrepreneur, and CEO, Noubar has cofounded and helped build over 70 life science and technology startups. Prior to founding Flagship Pioneering, Noubar was the founder and CEO of PerSeptive Biosystems, a leader in bio-instrumentation that grew to $100 million in annual revenues. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation in 1998, he became senior vice president and chief business officer of Applera, where he initiated and oversaw the creation of Celera Genomics.

Noubar is also co-founder and Board Chairman of Moderna, Generate Biomedicines, Tessera Therapeutics, Alltrna, Apriori Bio, and ProFound Therapeutics. Previously, he was a member of the founding team, director, and investor in highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millenium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb), and Affinnova (acquired by AC Nielsen).

Noubar entered biotechnology during its emergence as an academic field and industry, completing his doctoral work in biochemical engineering at MIT in 1987. He has written numerous scientific publications and is the inventor of over 100 patents. He was a senior lecturer at MIT’s Sloan School of Management from 2000 to 2016, and a lecturer at Harvard Business School until 2020. He teaches and speaks around the world on topics ranging from entrepreneurship, innovation, and economic development to biological engineering, new medicines, and renewable energy.

Noubar’s commitment to improving the human condition through science and business goes hand in hand with social investments and a global humanitarian initiative. Together with his partners, he has launched philanthropic projects including the Aurora Humanitarian Initiative, FAST Foundation, and the UWC Dilijan School. Noubar is a member of the Corporation of MIT (the Institute’s governing body) and a member of the board of trustees for the Boston Symphony Orchestra.

Noubar was born in Beirut to Armenian parents in 1962, did his undergraduate work at McGill University in Montreal, and completed his Ph.D. in biochemical engineering at MIT in 1987. A passionate advocate of the contributions of immigrants to economic and scientific progress, Noubar received the Golden Door Award in 2017 from the International Institute of New England, in honor of his outstanding contributions to American society as a U.S citizen of foreign birth. He was also awarded a Great Immigrant honor from the Carnegie Corporation in 2016, received a Technology Pioneer award from the World Economic Forum in 2012, and was presented with the Ellis Island Medal of Honor in 2008. In 2022, Noubar was elected to the National Academy of Engineering.

Nader has served as an Observer of the board of directors of Inari Agriculture, the Boston-based company which uses its proprietary AI-powered predictive design and multiplex gene editing toolbox to create high performing plant varieties to sustainably improve agriculture, since June 2019. Nader has also served as a member of the board of directors of FreshToHome, India’s largest fully integrated omnichannel brand in fresh fish and meat, since September 2020. More recently, he has also served as an Observer of the board of directors of Wholsum Foods, the parent company of the award-winning children's food brand Slurrp Farm and the adult’s focused supergrain food brand Millé, since February 2022. Nader also serves on the limited partners advisory board of several venture and growth focused investment funds. Before joining ICD, he worked in investment banking at Bank of America Merrill Lynch from July 2010 until September 2015.

Nader holds a Master’s in Management from the EDHEC Business School in France and a Master of Science in Finance from the EBS Oestrich-Winkel in Germany. Nader is a Kauffman Fellow.